Affinity Proteomics‐Based Non‐Invasive Detection of Clinically Significant Liver Disease
Alimentary Pharmacology & Therapeutics · 2026-07 · 64 (1) · 74-88
DOI: 10.1111/apt.70656 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 16.04.2026. Verfasst von Sriram Balasubramani und 14 weiteren Autor:innen. Beteiligte Einrichtung: Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, Health Care Provider of the European Reference Network on Rare Liver Dis…. Hauptthemen laut MEDLINE: Liver Diseases, Proteomics. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Association for the Study of the Liver, CSL Behring, Arrowhead Pharmaceuticals.
Abstract (Originalsprache)
Background
Non‐invasive biomarkers predicting major adverse liver outcomes (MALO) are urgently needed.
Aims
We assessed a novel, proximity extension assay‐based high‐throughput targeted proteomics.
Methods
Plasma proteomic data (> 2900 proteins) and clinical information were accessed from the population‐based UK Biobank cohort, comprising ~52,000 individuals with a median follow‐up of > 10 years, including obese (~12,700) and diabetic (~1500) participants. Validation cohorts comprised 287 participants with severe alpha1‐antitrypsin deficiency (Pi*ZZ genotype), and 960 people living with HIV, who underwent liver stiffness measurement (LSM) via transient elastography. Selected proteomic parameters were compared to routine measurements. Bayes‐moderated linear models (covariates: age and sex) assessed the differential abundance. Logistic regression was used to develop and validate a prognostic score.
Results
Routine gamma‐glutamyltransferase (GGT) and aspartate aminotransferase (AST) strongly correlated with proteomic measurements ( r = 0.92 and r = 0.71, respectively). Similarly, proteomic‐based thrombospondin‐2 levels correlated with immunoassay‐based values ( r = 0.85). Twenty proteins were consistently associated with future MALOs/increased liver stiffness in all cohorts. A novel five‐component proteomic score derived from the UK Biobank cohort demonstrated superior predictive power for MALOs (AUROC = 0.84) compared to AST‐to‐platelet‐ratio index (AUROC = 0.73) and Fibrosis‐4 index (AUROC = 0.72), with stable performance in obese and diabetic subcohorts. In people living with HIV and alpha1‐antitrypsin deficiency patients, all five components increased across fibrosis stages and the proteomic score outperformed AST‐to‐platelet‐ratio/Fibrosis‐4 index in predicting significant LSM‐based liver fibrosis.
Conclusions
We identify a new proteomic score comprising epithelial/hepatic stellate cell markers that yields a robust predictive performance across different liver disease aetiologies. Thereby, we demonstrate the usefulness of emerging proteomic techniques in hepatology. Trial Registration The registry study is listed at ClinicalTrials.gov (NCT02929940)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE LIVER), University Hospital RWTH Aachen, Aachen, Germ…
- Department of Gastroenterology and Hepatology, Medical University Lausitz-Carl-Thiem, Cottbus, Germany.
- Sanofi, Cambridge, Massachusetts, USA.
- Department of Internal Medicine, Radboud University Medical Centre, Nijmegen, the Netherlands.
- Department of Medical Genetics, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
- Prague University of Economics and Business, Prague, Czech Republic.
ORCID-Profile: Malin Fromme
Förderung
- European Association for the Study of the Liver
- CSL Behring
- Arrowhead Pharmaceuticals
- German Liver Foundation
Zitieren
APA
Balasubramani, S., Remih, K., Karl, A. S., Borchert, J. A., Schrader, C., Fromme, M., Kayatekin, C., Zhang, B., Levit, M., Krishnaswami, P., van Eekeren, L. E., Joosten, L. A. B., Otten, T., Tomanová, P., & Strnad, P. (2026). Affinity Proteomics‐Based Non‐Invasive Detection of Clinically Significant Liver Disease. Alimentary Pharmacology & Therapeutics, 64(1), 74-88. https://doi.org/10.1111/apt.70656
Vancouver
Balasubramani S, Remih K, Karl AS, Borchert JA, Schrader C, Fromme M, et al. Affinity Proteomics‐Based Non‐Invasive Detection of Clinically Significant Liver Disease. Alimentary Pharmacology & Therapeutics. 2026;64(1):74-88. doi:10.1111/apt.70656
BibTeX
@article{Balasubramani2026,
author = {Balasubramani, Sriram and Remih, Katharina and Karl, Anna Sophie and Borchert, Julia Alexandra and Schrader, Christina and Fromme, Malin and Kayatekin, Can and Zhang, Bailin and Levit, Mikhail and Krishnaswami, Pavithra and van Eekeren, Louise E and Joosten, Leo A B and Otten, Twan and Tomanová, Petra and Strnad, Pavel},
title = {Affinity Proteomics‐Based Non‐Invasive Detection of Clinically Significant Liver Disease},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
volume = {64},
number = {1},
pages = {74--88},
doi = {10.1111/apt.70656}
}
EUVIMED